LT3484921T - Anti-il-22r antikūnai - Google Patents
Anti-il-22r antikūnaiInfo
- Publication number
- LT3484921T LT3484921T LTEPPCT/EP2017/067923T LTEP2017067923T LT3484921T LT 3484921 T LT3484921 T LT 3484921T LT EP2017067923 T LTEP2017067923 T LT EP2017067923T LT 3484921 T LT3484921 T LT 3484921T
- Authority
- LT
- Lithuania
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612337.4A GB201612337D0 (en) | 2016-07-15 | 2016-07-15 | Ant-il-22r antibodies |
| PCT/EP2017/067923 WO2018011420A1 (en) | 2016-07-15 | 2017-07-14 | Anti-il-22r antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3484921T true LT3484921T (lt) | 2022-01-10 |
Family
ID=56890507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2017/067923T LT3484921T (lt) | 2016-07-15 | 2017-07-14 | Anti-il-22r antikūnai |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10696741B2 (enExample) |
| EP (2) | EP3484921B1 (enExample) |
| JP (1) | JP7163275B2 (enExample) |
| KR (2) | KR102571012B1 (enExample) |
| CN (1) | CN109641966B (enExample) |
| AU (1) | AU2017296094B2 (enExample) |
| BR (1) | BR112019000788A2 (enExample) |
| CA (1) | CA3024370A1 (enExample) |
| CY (1) | CY1125041T1 (enExample) |
| DK (1) | DK3484921T3 (enExample) |
| ES (1) | ES2903412T3 (enExample) |
| GB (1) | GB201612337D0 (enExample) |
| HR (1) | HRP20220197T1 (enExample) |
| HU (1) | HUE057615T2 (enExample) |
| IL (1) | IL264262B2 (enExample) |
| LT (1) | LT3484921T (enExample) |
| MX (1) | MX2019000539A (enExample) |
| MY (1) | MY197821A (enExample) |
| PL (1) | PL3484921T3 (enExample) |
| PT (1) | PT3484921T (enExample) |
| RS (1) | RS62884B1 (enExample) |
| RU (1) | RU2758721C2 (enExample) |
| SA (1) | SA519400856B1 (enExample) |
| SG (1) | SG11201900128XA (enExample) |
| SI (1) | SI3484921T1 (enExample) |
| UA (1) | UA125585C2 (enExample) |
| WO (1) | WO2018011420A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
| KR20210019464A (ko) * | 2018-06-05 | 2021-02-22 | 바이오아트라, 인코퍼레이티드 | 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도 |
| CN110302363B (zh) * | 2019-07-04 | 2020-10-09 | 北京大学第三医院（北京大学第三临床医学院） | Il-22作为制备治疗pcos药物的应用及药物制剂 |
| JP7789368B2 (ja) * | 2020-05-29 | 2025-12-22 | 学校法人 久留米大学 | 炎症性腸疾患に対する治療用抗体 |
| EP4531804A1 (en) | 2022-06-03 | 2025-04-09 | LEO Pharma A/S | Liquid formulation of il-22r antibody |
| WO2024184333A1 (en) | 2023-03-08 | 2024-09-12 | Leo Pharma A/S | Il-22r antibody for use in treating atopic dermatitis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| AU2004223837C1 (en) * | 2003-03-24 | 2012-03-15 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| BRPI0516975A (pt) * | 2004-10-22 | 2008-09-30 | Zymogenetics Inc | anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno |
| WO2007126439A2 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| PH12012500924A1 (en) * | 2009-11-19 | 2012-11-26 | Merck Serono Sa | Humanized antibodies against human il-22ra |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| US20140359902A1 (en) * | 2011-12-16 | 2014-12-04 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| IN2015DN00140A (enExample) * | 2012-08-31 | 2015-06-12 | Argen X Bv | |
| WO2014133728A2 (en) * | 2013-03-01 | 2014-09-04 | Albert Einstein College Of Medicine Of Yeshiva University | Hhla2 as a novel inhibitor of human immune system and uses thereof |
| CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
-
2016
- 2016-07-15 GB GBGB1612337.4A patent/GB201612337D0/en not_active Ceased
-
2017
- 2017-07-14 ES ES17746011T patent/ES2903412T3/es active Active
- 2017-07-14 WO PCT/EP2017/067923 patent/WO2018011420A1/en not_active Ceased
- 2017-07-14 EP EP17746011.0A patent/EP3484921B1/en active Active
- 2017-07-14 CN CN201780053328.1A patent/CN109641966B/zh active Active
- 2017-07-14 SI SI201731037T patent/SI3484921T1/sl unknown
- 2017-07-14 PL PL17746011T patent/PL3484921T3/pl unknown
- 2017-07-14 LT LTEPPCT/EP2017/067923T patent/LT3484921T/lt unknown
- 2017-07-14 RS RS20220105A patent/RS62884B1/sr unknown
- 2017-07-14 IL IL264262A patent/IL264262B2/en unknown
- 2017-07-14 BR BR112019000788-1A patent/BR112019000788A2/pt active Search and Examination
- 2017-07-14 RU RU2019103991A patent/RU2758721C2/ru active
- 2017-07-14 KR KR1020197001500A patent/KR102571012B1/ko active Active
- 2017-07-14 HU HUE17746011A patent/HUE057615T2/hu unknown
- 2017-07-14 UA UAA201901458A patent/UA125585C2/uk unknown
- 2017-07-14 PT PT177460110T patent/PT3484921T/pt unknown
- 2017-07-14 SG SG11201900128XA patent/SG11201900128XA/en unknown
- 2017-07-14 MY MYPI2018002752A patent/MY197821A/en unknown
- 2017-07-14 DK DK17746011.0T patent/DK3484921T3/da active
- 2017-07-14 MX MX2019000539A patent/MX2019000539A/es unknown
- 2017-07-14 HR HRP20220197TT patent/HRP20220197T1/hr unknown
- 2017-07-14 JP JP2019501641A patent/JP7163275B2/ja active Active
- 2017-07-14 KR KR1020237028376A patent/KR20230128137A/ko not_active Ceased
- 2017-07-14 CA CA3024370A patent/CA3024370A1/en active Pending
- 2017-07-14 EP EP21208038.6A patent/EP4023674A3/en not_active Withdrawn
- 2017-07-14 AU AU2017296094A patent/AU2017296094B2/en active Active
-
2019
- 2019-01-08 US US16/242,760 patent/US10696741B2/en active Active
- 2019-01-10 SA SA519400856A patent/SA519400856B1/ar unknown
- 2019-10-23 US US16/661,783 patent/US11447544B2/en active Active
- 2019-10-23 US US16/661,757 patent/US11261246B2/en active Active
-
2022
- 2022-02-04 CY CY20221100099T patent/CY1125041T1/el unknown
- 2022-08-11 US US17/819,161 patent/US20230088269A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| PT3606954T (pt) | Anticorpos anti-lag3 | |
| EP3481869A4 (en) | ANTI-CD73 ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| IL251963A0 (en) | Anti-pd-1 antibodies | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| DK3350218T5 (da) | Polyomavirus-neutraliserende antistoffer | |
| HUE060878T2 (hu) | Anti-transztiretin antitestek | |
| PL3556777T3 (pl) | Konstrukty przeciwciał wieloswoistych | |
| PT3101032T (pt) | Onjugado de anticorpo anti-her2-fármaco | |
| IL256099A (en) | Antibody | |
| DK3529269T3 (da) | Antistof-konstruktioner | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| EP3319983C0 (en) | TAU LINKING ANTIBODIES | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| IL291164A (en) | Anti-nme antibody | |
| EP3532034A4 (en) | ANTI-APOE ANTIBODY | |
| IL257368A (en) | Antibody | |
| EP3579879A4 (en) | ANTI-BODY ANTI-KIR3DL1 | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3452515T3 (da) | Her-2-bindende antistoffer |